These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9624235)

  • 1. Pharmacokinetics of anticancer agents in patients with impaired liver function.
    Donelli MG; Zucchetti M; Munzone E; D'Incalci M; Crosignani A
    Eur J Cancer; 1998 Jan; 34(1):33-46. PubMed ID: 9624235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of impaired liver function on the elimination of antineoplastic agents.
    Koren G; Beatty K; Seto A; Einarson TR; Lishner M
    Ann Pharmacother; 1992 Mar; 26(3):363-71. PubMed ID: 1554959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review.
    Pérez-Pitarch A; Guglieri-López B; Nacher A; Merino V; Merino-Sanjuán M
    Nutr Cancer; 2017; 69(4):555-563. PubMed ID: 28353359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of the taxanes including nab-paclitaxel.
    Joerger M
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment regimens of classical and newer taxanes.
    Joerger M
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):221-33. PubMed ID: 26589792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions with the taxanes: clinical implications.
    Baker AF; Dorr RT
    Cancer Treat Rev; 2001 Aug; 27(4):221-33. PubMed ID: 11545542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
    Danesi R; Conte PF; Del Tacca M
    Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
    Panday VR; Huizing MT; Willemse PH; De Graeff A; ten Bokkel Huinink WW; Vermorken JB; Beijnen JH
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-34-S11-38. PubMed ID: 9314297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of vinca alkaloids.
    Rahmani R; Zhou XJ
    Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
    Twelves C; Glynne-Jones R; Cassidy J; Schüller J; Goggin T; Roos B; Banken L; Utoh M; Weidekamm E; Reigner B
    Clin Cancer Res; 1999 Jul; 5(7):1696-702. PubMed ID: 10430071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
    Zamora JM; Pearce HL; Beck WT
    Mol Pharmacol; 1988 Apr; 33(4):454-62. PubMed ID: 3162758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
    Beck WT; Cirtain MC; Look AT; Ashmun RA
    Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacology of the taxanes: implications of the differences.
    Gligorov J; Lotz JP
    Oncologist; 2004; 9 Suppl 2():3-8. PubMed ID: 15161985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction.
    Briasoulis E; Karavasilis V; Tzamakou E; Piperidou C; Soulti K; Pavlidis N
    Anticancer Drugs; 2006 Nov; 17(10):1219-22. PubMed ID: 17075322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical pharmacology of vinca alkaloids.
    Zhou XJ; Rahmani R
    Drugs; 1992; 44 Suppl 4():1-16; discussion 66-9. PubMed ID: 1283846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photochemical Internalization Using Natural Anticancer Drugs, Antimetabolites, and Nanoformulations: A Systematic Study against Breast and Pancreatic Cancer Cell Lines.
    Barnett C; Joubert F; Iliopoulou A; Álvarez RS; Pasparakis G
    Mol Pharm; 2023 Mar; 20(3):1818-1841. PubMed ID: 36802639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.